Acuta Capital Partners, LLC Bellus Health Inc. Transaction History

Acuta Capital Partners, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$8.22 - $10.76 $6.63 Million - $8.67 Million	-806,000 Reduced 56.03%	632,500 $5.2 Million
Q3 2022 Nov 14, 2022	BUY	$8.95 - $12.0 $5.57 Million - $7.47 Million	622,500 Added 76.29%	1,438,500 $15.2 Million
Q1 2022 May 16, 2022	BUY	$5.56 - $7.99 $1.62 Million - $2.33 Million	291,000 Added 55.43%	816,000 $5.61 Million
Q4 2021 Feb 14, 2022	SELL	$5.26 - $8.3 $7.8 Million - $12.3 Million	-1,482,500 Reduced 73.85%	525,000 $4.23 Million
Q3 2021 Nov 15, 2021	BUY	$2.7 - $6.64 $5.42 Million - $13.3 Million	2,007,500 New	2,007,500 $12.3 Million
Q3 2020 Nov 16, 2020	SELL	$2.14 - $12.02 $1.64 Million - $9.2 Million	-765,000 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$8.88 - $11.15 $2.71 Million - $3.4 Million	-305,000 Reduced 28.5%	765,000 $7.87 Million
Q1 2020 May 15, 2020	BUY	$5.77 - $10.85 $1.5 Million - $2.82 Million	260,000 Added 32.1%	1,070,000 $10.7 Million
Q4 2019 Feb 14, 2020	BUY	$5.76 - $7.6 $144,000 - $190,000	25,000 Added 3.18%	810,000 $6.16 Million
Q3 2019 Nov 14, 2019	BUY	$6.24 - $8.84 $4.9 Million - $6.94 Million	785,000 New	785,000 $5.02 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.